These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29451)

  • 1. Dopamine receptor mechanisms: behavioral and electrophysiological studies.
    Ungerstedt U; Ljungberg T; Schultz W
    Adv Biochem Psychopharmacol; 1978; 19():311-21. PubMed ID: 29451
    [No Abstract]   [Full Text] [Related]  

  • 2. Participation of an endogenous Ca++-blinding protein activator in the development of drug-induced supersensitivity of striatal dopamine receptors.
    Gnegy M; Uzunov P; Costa E
    J Pharmacol Exp Ther; 1977 Sep; 202(3):558-64. PubMed ID: 19618
    [No Abstract]   [Full Text] [Related]  

  • 3. Biochemical characteristics of D1 dopamine receptors: relationship to behavior and schizophrenia.
    Creese I; Hess EJ
    Clin Neuropharmacol; 1986; 9 Suppl 4():14-6. PubMed ID: 2882838
    [No Abstract]   [Full Text] [Related]  

  • 4. Dopaminergic receptor activity in substantia nigra in the mechanisms of autoregulation of striatal dopamine release.
    Groppetti A; Parenti M; Cattabeni F; Maggi A; De Angelis L; Monduzzi M; Racagni G
    Adv Biochem Psychopharmacol; 1978; 19():363-71. PubMed ID: 696464
    [No Abstract]   [Full Text] [Related]  

  • 5. Neuroleptic drugs and their action on different neuronal pathways.
    Ungerstedt U; Herrera-Marschitz M; Forster C
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):34-7. PubMed ID: 2858478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No evidence for increased dopamine receptor binding in superresponsive mice after a single dose of neuroleptics.
    Hyttel J
    Adv Biochem Psychopharmacol; 1980; 24():167-73. PubMed ID: 6105773
    [No Abstract]   [Full Text] [Related]  

  • 7. Ergot drugs and central monoaminergic mechanisms: a histochemical, biochemical and behavioral analysis.
    Fuxe K; Fredholm BB; Ogren SO; Agnati LF; Hökfelt T; Gustafsson JA
    Fed Proc; 1978 Jun; 37(8):2181-91. PubMed ID: 350633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dependence of the antipsychotic effect of neuroleptics on their dopamine-blocking properties].
    Arushanian EB
    Farmakol Toksikol; 1982; 45(5):118-26. PubMed ID: 6128251
    [No Abstract]   [Full Text] [Related]  

  • 9. Gamma-type endorphins and brain dopaminergic systems.
    van Ree JM; Elands J; Kiraly I; Wolterink G
    Prog Clin Biol Res; 1990; 328():287-90. PubMed ID: 1968266
    [No Abstract]   [Full Text] [Related]  

  • 10. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular dopamine receptor as a model for other dopamine receptors.
    Goldberg LI
    Adv Biochem Psychopharmacol; 1978; 19():119-29. PubMed ID: 358776
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug effects on pre- and postsynaptic dopamine receptors.
    Andén NE; Grabowska-Andén M
    Adv Biochem Psychopharmacol; 1980; 24():57-64. PubMed ID: 6105802
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of the effects of neuroleptic drugs on pre- and postsynaptic dopaminergic mechanisms in the rat striatum.
    Iversen LL; Rogawski MA; Miller RJ
    Mol Pharmacol; 1976 Mar; 12(2):251-62. PubMed ID: 4724
    [No Abstract]   [Full Text] [Related]  

  • 14. Two distinct classes of dopamine receptor mediating actions of antipsychotics: binding and behavioral studies.
    Sokoloff P; Martres MP; Protais P; Costentin J; Schwartz JC
    Adv Biochem Psychopharmacol; 1983; 36():163-73. PubMed ID: 6134435
    [No Abstract]   [Full Text] [Related]  

  • 15. The pathophysiology of tardive dyskinesia.
    Klawans HL; Carvey P; Tanner CM; Goetz CG
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Action of etmozin and ethacizin on dopaminergic adenylate cyclase of the striate system of the brain].
    Baldenkov GN; Ratner EI; Rozenshtraukh LV; Tkachuk VA
    Biull Eksp Biol Med; 1984 Oct; 98(10):448-50. PubMed ID: 6149776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioural data suggesting the plurality of central dopamine receptors.
    Costentin J; Dubuc I; Protais P
    Adv Biochem Psychopharmacol; 1983; 37():289-97. PubMed ID: 6138951
    [No Abstract]   [Full Text] [Related]  

  • 18. Dopamine-sensitive adenylate cyclase and receptor binding activities after acute and chronic neuroleptic drug treatment.
    Clement-Cormier Y
    Adv Biochem Psychopharmacol; 1980; 24():103-11. PubMed ID: 6105768
    [No Abstract]   [Full Text] [Related]  

  • 19. Evidence for the existence of regulatory DA receptors in the substantia nigra.
    Di Chiara G; Mereu GP; Vargiu L; Porceddu ML; Mulas A; Trabucchi M; Spano PF
    Adv Biochem Psychopharmacol; 1977; 16():477-81. PubMed ID: 18896
    [No Abstract]   [Full Text] [Related]  

  • 20. Chronic sulpiride treatment produces supersensitivity of striatal adenylate cyclase to dopamine in sexually immature or adult castrated rats.
    Gnegy ME; Bernabei A; Treisman G
    J Pharmacol Exp Ther; 1983 Mar; 224(3):627-33. PubMed ID: 6827485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.